Literature DB >> 17951639

Modification of the N-glycosylation pathway to produce homogeneous, human-like glycans using GlycoSwitch plasmids.

Wouter Vervecken1, Nico Callewaert, Vladimir Kaigorodov, Steven Geysens, Roland Contreras.   

Abstract

Glycosylation is an important issue in heterologous protein production for therapeutic applications. Glycoproteins produced in Pichia pastoris contain high mannose glycan structures that can hamper downstream processing, might be immunogenic, and cause rapid clearance from the circulation. This chapter describes a method that helps solving these glycosylation-related problems by inactivation of OCH1, overexpression of an HDEL-tagged mannosidase, and overexpression of a Kre2/GlcNAc-transferase I chimeric enzyme. Different plasmids are described as well as glycan analysis methods.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17951639     DOI： 10.1007/978-1-59745-456-8_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  9 in total

1.  Remodeling of the glycosylation pathway in the methylotrophic yeast Hansenula polymorpha to produce human hybrid-type N-glycans.

Authors:  Seon Ah Cheon; Hyunah Kim; Doo-Byoung Oh; Ohsuk Kwon; Hyun Ah Kang
Journal:  J Microbiol       Date:  2012-04-27       Impact factor: 3.422

Review 2.  Current strategies for protein production and purification enabling membrane protein structural biology.

Authors:  Aditya Pandey; Kyungsoo Shin; Robin E Patterson; Xiang-Qin Liu; Jan K Rainey
Journal:  Biochem Cell Biol       Date:  2016-01-20       Impact factor: 3.626

3.  Consequences of the Endogenous N-Glycosylation of Human Ribonuclease 1.

Authors:  Valerie T Ressler; Ronald T Raines
Journal:  Biochemistry       Date:  2019-01-29       Impact factor: 3.162

Review 4.  Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.

Authors:  Isabelle Legastelois; Sophie Buffin; Isabelle Peubez; Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

5.  Expression of recombinant human mast cell chymase with Asn-linked glycans in glycoengineered Pichia pastoris.

Authors:  Eliot T Smith; Evan T Perry; Megan B Sears; David A Johnson
Journal:  Protein Expr Purif       Date:  2014-08-12       Impact factor: 1.650

6.  Production of biologically active complement factor H in therapeutically useful quantities.

Authors:  Christoph Q Schmidt; Fern C Slingsby; Anna Richards; Paul N Barlow
Journal:  Protein Expr Purif       Date:  2010-12-10       Impact factor: 1.650

7.  Engineering the yeast Yarrowia lipolytica for the production of therapeutic proteins homogeneously glycosylated with Man₈GlcNAc₂ and Man₅GlcNAc₂.

Authors:  Karen De Pourcq; Wouter Vervecken; Isabelle Dewerte; Albena Valevska; Annelies Van Hecke; Nico Callewaert
Journal:  Microb Cell Fact       Date:  2012-05-01       Impact factor: 5.328

8.  Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care.

Authors:  Pablo Perez-Pinera; Ningren Han; Sara Cleto; Jicong Cao; Oliver Purcell; Kartik A Shah; Kevin Lee; Rajeev Ram; Timothy K Lu
Journal:  Nat Commun       Date:  2016-07-29       Impact factor: 14.919

Review 9.  Tuning microbial hosts for membrane protein production.

Authors:  Maria Freigassner; Harald Pichler; Anton Glieder
Journal:  Microb Cell Fact       Date:  2009-12-29       Impact factor: 5.328
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.